$23.83
+0.52
(+2.23%)▲
Live
Revenue is up for the last 2 quarters, 512.0K → 1.82M (in $), with an average increase of 72.0% per quarter
Netprofit is up for the last 2 quarters, -62.55M → -60.17M (in $), with an average increase of 4.0% per quarter
2.22%
Downside
Day's Volatility :3.32%
Upside
1.12%
41.92%
Downside
52 Weeks Volatility :49.56%
Upside
13.16%
Period | CHINOOK THERAPEUTICS INC | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 6.83% | 0.3% | -6.7% |
6 Months | 2.91% | -8.3% | -6.2% |
1 Year | 53.56% | -4.8% | -6.3% |
3 Years | 38.34% | 23.8% | 26.9% |
Market Capitalization | 1.6B |
Book Value | $6.17 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.23 |
Wall Street Target Price | 36.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -3843.62% |
Return On Assets TTM | -23.5% |
Return On Equity TTM | -51.56% |
Revenue TTM | 5.3M |
Revenue Per Share TTM | 0.08 |
Quarterly Revenue Growth YOY | -32.2% |
Gross Profit TTM | -135.1M |
EBITDA | -197.0M |
Diluted Eps TTM | -3.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.23 |
EPS Estimate Next Year | -3.45 |
EPS Estimate Current Quarter | -0.79 |
EPS Estimate Next Quarter | -0.81 |
What analysts predicted
Upside of 51.07%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 17.3M | - |
Net Income | -82.4M | - |
Net Profit Margin | -477.3% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 827.0K | ↓ 95.21% |
Net Income | -81.6M | ↓ 0.91% |
Net Profit Margin | -9.9K% | ↓ 9392.35% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 51.6K | ↓ 93.76% |
Net Income | -102.9K | ↓ 99.87% |
Net Profit Margin | -199.39% | ↑ 9670.26% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 6.1M | ↑ 11770.22% |
Net Income | -187.9M | ↑ 182404.83% |
Net Profit Margin | -3.1K% | ↓ 2866.29% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | -375.4K | ↓ 9484.37% |
Net Income | 110.4M | ↓ 459.59% |
Net Profit Margin | -29.4K% | ↑ 737994.99% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.7M | ↓ 818.48% |
Net Income | -31.7M | ↓ 128.7% |
Net Profit Margin | -1.2K% | ↑ 28230.22% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 418.0K | ↓ 84.5% |
Net Income | -37.6M | ↑ 18.82% |
Net Profit Margin | -9.0K% | ↓ 7831.91% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.5M | ↑ 498.33% |
Net Income | -56.0M | ↑ 48.69% |
Net Profit Margin | -2.2K% | ↑ 6768.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 512.0K | ↓ 79.53% |
Net Income | -62.6M | ↑ 11.75% |
Net Profit Margin | -12.2K% | ↓ 9979.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8M | ↑ 257.03% |
Net Income | -60.2M | ↓ 3.8% |
Net Profit Margin | -3.3K% | ↑ 8925.62% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 291.3M | - |
Total Liabilities | 225.7M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 384.5M | ↑ 31.98% |
Total Liabilities | 94.4M | ↓ 58.19% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 563.8M | ↑ 46.65% |
Total Liabilities | 110.2M | ↑ 16.72% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 574.1M | ↑ 1.82% |
Total Liabilities | 132.1M | ↑ 19.96% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 563.8M | ↑ 47.1% |
Total Liabilities | 110.2M | ↓ 2.95% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 531.3M | ↓ 5.77% |
Total Liabilities | 104.5M | ↓ 5.16% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 601.2M | ↑ 13.17% |
Total Liabilities | 94.1M | ↓ 9.92% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 590.3M | ↓ 1.81% |
Total Liabilities | 115.7M | ↑ 22.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 574.1M | ↓ 2.75% |
Total Liabilities | 132.1M | ↑ 14.21% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 543.9M | ↓ 5.26% |
Total Liabilities | 131.5M | ↓ 0.5% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.0K | - |
Investing Cash Flow | -758.0K | - |
Financing Cash Flow | 6.0K | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.6M | ↑ 226366.67% |
Investing Cash Flow | -758.0K | ↑ 0.0% |
Financing Cash Flow | 25.7M | ↑ 428000.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -55.8M | ↑ 311.01% |
Investing Cash Flow | 109.7M | ↓ 14568.6% |
Financing Cash Flow | 124.3M | ↑ 383.89% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -102.7M | ↑ 83.97% |
Investing Cash Flow | -112.6M | ↓ 202.71% |
Financing Cash Flow | 209.5M | ↑ 68.57% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.5M | ↓ 9.01% |
Investing Cash Flow | -77.7M | ↑ 2769.69% |
Financing Cash Flow | 173.6M | ↑ 66929.34% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.7M | ↑ 9.87% |
Investing Cash Flow | -55.6M | ↓ 28.51% |
Financing Cash Flow | 1.8M | ↓ 98.98% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.6M | ↑ 23.85% |
Investing Cash Flow | -33.8M | ↓ 39.25% |
Financing Cash Flow | 107.1M | ↑ 5977.2% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.3M | ↓ 17.33% |
Investing Cash Flow | -13.1M | ↓ 61.11% |
Financing Cash Flow | 18.8M | ↓ 82.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -50.7M | ↑ 37.58% |
Investing Cash Flow | 32.4M | - |
Financing Cash Flow | 21.3M | ↓ 10.25% |
Sell
Neutral
Buy
CHINOOK THERAPEUTICS INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() CHINOOK THERAPEUTICS INC | 17.49% | 2.91% | 53.56% | 38.34% | -45.79% |
![]() Moderna, Inc. | -5.37% | -28.24% | -13.14% | 103.02% | 578.71% |
![]() Regeneron Pharmaceuticals, Inc. | -10.12% | -3.55% | 9.07% | 20.95% | 140.97% |
![]() Seagen, Inc. | -2.85% | 59.4% | 42.61% | 21.68% | 240.77% |
![]() Vertex Pharmaceuticals Incorporated | -4.35% | 4.3% | 22.83% | 15.12% | 110.67% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() CHINOOK THERAPEUTICS INC | NA | NA | NA | -3.23 | -0.52 | -0.23 | 0.0 | 6.17 |
![]() Moderna, Inc. | 11.22 | 11.22 | 0.0 | -1.83 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.53 | 26.53 | 0.41 | 13.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() CHINOOK THERAPEUTICS INC | Buy | $1.6B | -45.79% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $48.1B | 578.71% | 11.22 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 140.97% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.3B | 240.77% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.0B | 110.67% | 26.53 | 35.4% |
Samsara BioCapital, LLC
BlackRock Inc
Deep Track Capital, LP
Vanguard Group Inc
State Street Corporation
Octagon Capital Advisors LP
CHINOOK THERAPEUTICS INC’s price-to-earnings ratio stands at None
Read MoreChinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.
Organization | CHINOOK THERAPEUTICS INC |
Employees | 214 |
CEO | Mr. Eric L. Dobmeier J.D. |
Industry | Health Technology |
First Majestic Silver Corp
$5.65
-1.74%
ONYX ACQUISITION CO. I
$10.50
-4.55%
Diversified Healthcare Trust
$1.25
+9.65%
ALTC ACQUISITION CORP-CL A
$10.68
+0.28%
iShares Morningstar Value ETF
$63.25
-0.25%
Nationwide Nasdaq-100 Risk-Managed Income ETF
$20.50
+0.1%
ENFUSION INC
$7.81
-0.89%
WisdomTree Trust - WisdomTree International Quality Dividend Growth Fund
$33.45
-1.21%
GIGACLOUD TECHNOLOGY INC
$6.71
+4.03%